Form 8-K - Current report:
SEC Accession No. 0001279569-16-004285
Filing Date
2016-09-01
Accepted
2016-09-01 07:12:23
Documents
8
Period of Report
2016-08-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K v448174_8k.htm 8-K 45087
2 EXHIBIT 2.1 v448174_ex2-1.htm EX-2.1 788044
3 EXHIBIT 2.2 v448174_ex2-2.htm EX-2.2 33873
4 EXHIBIT 10.1 v448174_ex10-1.htm EX-10.1 87078
5 EXHIBIT 10.2 v448174_ex10-2.htm EX-10.2 90911
6 EXHIBIT 99.1 v448174_ex99-1.htm EX-99.1 40373
7 GRAPHIC image_007.jpg GRAPHIC 2918
8 GRAPHIC image_006.jpg GRAPHIC 1839
  Complete submission text file 0001279569-16-004285.txt   1093310
Mailing Address 828 RICHMOND STREET WEST TORONTO A6 M6J 1C9
Business Address 828 RICHMOND STREET WEST TORONTO A6 M6J 1C9 416-703-2449
Cynapsus Therapeutics Inc. (Filer) CIK: 0001532079 (see all company filings)

EIN.: 981226819 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37426 | Film No.: 161864541
SIC: 2834 Pharmaceutical Preparations